Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16774943
Burdick AD, Ivnitski-Steele ID, Lauer FT, Burchiel SW (2006) PYK2 mediates anti-apoptotic AKT signaling in response to benzo[a]pyrene diol epoxide in mammary epithelial cells. Carcinogenesis 27, 2331-40 16774943
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BPDE increase
AG1478 BPDE inhibit treatment-induced increase
BAPTA-AM BPDE inhibit treatment-induced increase
LY294002 BPDE inhibit treatment-induced increase
PD98059 BPDE no effect upon treatment-induced increase
SB203580 BPDE no effect upon treatment-induced increase possible small inhibition of increase
BPDE Pyk2 (human) increase
AG1478 decrease small decrease
BAPTA-AM decrease
thapsigargin increase
AG1478 thapsigargin inhibit treatment-induced increase
LY294002 decrease
PD98059 increase
SB203580 no change compared to control
ionomycin increase
AG1478 ionomycin inhibit treatment-induced increase
A23187 increase
AG1478 A23187 inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
LY294002 EGF inhibit treatment-induced increase
PD98059 EGF augment treatment-induced increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BPDE increase
AG1478 BPDE inhibit treatment-induced increase
BAPTA-AM BPDE inhibit treatment-induced increase
BPDE Pyk2 (human) no effect upon treatment-induced increase
LY294002 BPDE inhibit treatment-induced increase
PD98059 BPDE inhibit treatment-induced increase
SB203580 BPDE augment treatment-induced increase
AG1478 decrease
BAPTA-AM no change compared to control
Pyk2 (human) no change compared to control
LY294002 increase
PD98059 decrease
SB203580 increase
thapsigargin increase
AG1478 thapsigargin inhibit treatment-induced increase
ionomycin increase
AG1478 ionomycin inhibit treatment-induced increase
A23187 increase
AG1478 A23187 inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
LY294002 EGF no effect upon treatment-induced increase
PD98059 EGF inhibit treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BPDE increase
AG1478 BPDE inhibit treatment-induced increase
BAPTA-AM BPDE inhibit treatment-induced increase
BPDE Pyk2 (human) no effect upon treatment-induced increase
LY294002 BPDE inhibit treatment-induced increase
PD98059 BPDE inhibit treatment-induced increase
SB203580 BPDE augment treatment-induced increase
AG1478 decrease
BAPTA-AM no change compared to control
Pyk2 (human) no change compared to control
LY294002 increase
PD98059 decrease
SB203580 increase
thapsigargin increase
AG1478 thapsigargin inhibit treatment-induced increase
ionomycin increase
AG1478 ionomycin inhibit treatment-induced increase
A23187 increase
AG1478 A23187 inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
LY294002 EGF no effect upon treatment-induced increase
PD98059 EGF inhibit treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BPDE increase
AG1478 BPDE inhibit treatment-induced increase
BAPTA-AM BPDE inhibit treatment-induced increase
BPDE Pyk2 (human) no effect upon treatment-induced increase
LY294002 BPDE inhibit treatment-induced increase
PD98059 BPDE inhibit treatment-induced increase
SB203580 BPDE augment treatment-induced increase
AG1478 decrease
BAPTA-AM no change compared to control
Pyk2 (human) no change compared to control
LY294002 increase
PD98059 decrease
SB203580 increase
thapsigargin increase
AG1478 thapsigargin inhibit treatment-induced increase
ionomycin increase
AG1478 ionomycin inhibit treatment-induced increase
A23187 increase
AG1478 A23187 inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
LY294002 EGF no effect upon treatment-induced increase
PD98059 EGF inhibit treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BPDE increase
AG1478 BPDE inhibit treatment-induced increase
BAPTA-AM BPDE inhibit treatment-induced increase
BPDE Pyk2 (human) no effect upon treatment-induced increase
LY294002 BPDE inhibit treatment-induced increase
PD98059 BPDE inhibit treatment-induced increase
SB203580 BPDE augment treatment-induced increase
AG1478 decrease
BAPTA-AM no change compared to control
Pyk2 (human) no change compared to control
LY294002 increase
PD98059 decrease
SB203580 increase
thapsigargin increase
AG1478 thapsigargin inhibit treatment-induced increase
ionomycin increase
AG1478 ionomycin inhibit treatment-induced increase
A23187 increase
AG1478 A23187 inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
LY294002 EGF no effect upon treatment-induced increase
PD98059 EGF inhibit treatment-induced increase

S166-p - MDM2 (human)
Modsite: SsRRRAIsEtEENsD SwissProt Entrez-Gene
Orthologous residues
MDM2 (human): S166‑p, MDM2 (mouse): S163‑p, MDM2 (rat): S138‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BPDE increase
LY294002 BPDE inhibit treatment-induced increase
PD98059 BPDE no effect upon treatment-induced increase
SB203580 BPDE inhibit treatment-induced increase
LY294002 no change compared to control
PD98059 no change compared to control
SB203580 decrease

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BPDE increase
AG1478 BPDE augment treatment-induced increase
BAPTA-AM BPDE augment treatment-induced increase
BPDE Pyk2 (human) no effect upon treatment-induced increase
LY294002 BPDE augment treatment-induced increase
PD98059 BPDE augment treatment-induced increase
SB203580 BPDE no effect upon treatment-induced increase
AG1478 no change compared to control
BAPTA-AM increase
Pyk2 (human) decrease
LY294002 increase
PD98059 increase
SB203580 increase

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BPDE increase
AG1478 BPDE augment treatment-induced increase
BAPTA-AM BPDE augment treatment-induced increase
BPDE Pyk2 (human) no effect upon treatment-induced increase
LY294002 BPDE augment treatment-induced increase
PD98059 BPDE augment treatment-induced increase
SB203580 BPDE no effect upon treatment-induced increase
AG1478 no change compared to control
BAPTA-AM increase
Pyk2 (human) decrease
LY294002 increase
PD98059 increase
SB203580 increase

S15-p - p53 (human)
Modsite: PsVEPPLsQEtFsDL SwissProt Entrez-Gene
Orthologous residues
p53 (human): S15‑p, p53 iso2 (human): S15‑p, p53 iso4 (human): , p53 (mouse): S18‑p, p53 iso2 (mouse): S18‑p, p53 (rat): S15‑p, p53 (rabbit): S15‑p, p53 (green monkey): S15‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BPDE increase

S20-p - p53 (human)
Modsite: PLsQEtFsDLWkLLP SwissProt Entrez-Gene
Orthologous residues
p53 (human): S20‑p, p53 iso2 (human): S20‑p, p53 iso4 (human): , p53 (mouse): S23‑p, p53 iso2 (mouse): S23‑p, p53 (rat): S20‑p, p53 (rabbit): S20‑p, p53 (green monkey): S20‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BPDE increase

Y881-p - Pyk2 (human)
Modsite: DRTDDLVyLNVMELV SwissProt Entrez-Gene
Orthologous residues
Pyk2 (human): Y881‑p, Pyk2 iso2 (human): Y839‑p, Pyk2 (mouse): Y881‑p, Pyk2 (rat): Y881‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  MCF-10A (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BPDE increase
BAPTA-AM BPDE inhibit treatment-induced decrease
A23187 increase
BAPTA-AM A23187 inhibit treatment-induced increase